### **Sido Muncul**

**BUY** (unchanged)


Company Update | Consumer Staples | SIDO IJ | 25 April 2024

#### **Stock Data**

Target price	Rp890
Prior TP	Rp700
Current price	Rp725
Upside/downside	+22.7%
Shares outstanding (mn)	30,227
Market cap (Rp bn)	21,750
Free float	22%
Avg. 6m daily T/O (Rp bn)	19

#### **Price Performance**

	3M	6M	12M
Absolute	45.0%	22.9%	-11.6%
Relative to JCI	46.0%	18.2%	-15.1%
52w low/high (Rp)		48	86 – 820



#### **Major Shareholders**

PT Hotel Candi Baru 77.6%

#### **Lukito Supriadi**

PT Indo Premier Sekuritas lukito.supriadi@ipc.co.id +62 21 5088 7168 ext. 716

#### **Andrianto Saputra**

PT Indo Premier Sekuritas andrianto.saputra@ipc.co.id +62 21 5088 7168 ext. 712

# 1Q24: strong profit beat from robust sales growth and margin improvement

- SIDO delivered 1Q24 net profit of Rp390bn (+30% yoy) and came above ours/consensus expectation at 35/38% (vs. 5yr avg of 21%).
- 1Q24 GPM improved significantly to 59.3% (+608bps yoy) above ours' (56.9%) and may be sustainable for the rest of the year.
- We upgrade FY24/25F earnings by +10/11% to reflect better margins. Maintain our BUY call for SIDO with higher TP of Rp890.

#### 1Q24 net profit came above expectations

SIDO's 1Q24 net profit of Rp390bn (+30% yoy) was above ours/consensus expectations at 35/38% vs. 5yr average of 21%. Sales grew by +16.1% yoy driven by both domestic sales growths (c.15% yoy) on the back of election spending and social aid disbursement; and stellar export sales growth of 44% yoy which now contributed c.7% to total revenue. Notably, SIDO gave longer term of payment (c. 2 weeks) at end of Mar24 to ensure product availability during the Eid holidays. GPM's rose by +608bps yoy to 59.3% was driven by lower raw material costs for F&B segment and better economies of scale on positive volume growth across segments. On the other hand, opex/sales ratio improved from 13.3% in 1Q23 to 12.7% in 1Q24 on the back of strong sales growth. Total salary/sales ratio declined to 3.6% (vs. 1Q23's 4.3%), while A&P/sales actually rose to 5.7% yoy (vs. 1Q23's 3.8%). This led to a net profit margin expansion of +397bps yoy to 37.1% in 1Q24.

Highest ever GPM attainment on a segmental basis for herbal and F&B Segmentally, herbal/F&B segments grew by +13.3/20% yoy. F&B segment's GPM improved significantly by +1061bps to 41.8% (a quarterly record high) on the back of lower cost inputs while herbal segments' GPM recorded a new high in 1Q24 at 71.5%. The strong set of margins is deemed to be sustainable and may further improve if sugar and coffee prices normalize.

#### Maintain our BUY call with higher TP of Rp890

In sum, we upgrade FY24/25F earnings by +10/11% to reflect a stronger growth outlook and higher margins. La Nina expectations in 2H24F (for herbal demand) along with robust Malaysia's export trend for energy drinks are among drivers for the rest of the year. SIDO's exposure to US\$-related cost is manageable at 20-30% of COGS and is more insulated to Rupiah depreciation against US\$ compared to peers. In sum, we maintain our BUY call following 1Q24's stellar results with a higher TP of Rp890 based on 22.0x FY24F PE (+0.5s.d from its 5 year average).

Financial Summary (Rp bn)	2022A	2023A	2024F	2025F	2026F
Revenue	3,866	3,566	3,995	4,376	4,701
EBITDA	1,470	1,347	1,615	1,765	1,896
Net profit	1,105	951	1,212	1,322	1,416
EPS (Rp)	37	32	40	44	47
EPS growth	-12.4%	-13.9%	27.5%	9.1%	7.1%
ROE	31.3%	28.8%	35.0%	37.6%	41.0%
PER (x)	20.1	23.4	18.3	16.8	15.7
Dividend yield	4.9%	4.8%	4.8%	6.1%	6.7%
Forecast change			10%	11%	10%
IPS vs. consensus			117%	118%	113%

Source: Company, Indo Premier

Share price closing as of: 25 April 2024

# **INDOPREMIER**

Rep bn   1024   1023   % YoY   4023   % QoQ   PS   KPS   Cons   FY24F   % Cons   FY24F	Fig. 1: SIDO 1Q24 result summary										
COGS         (428)         (424)         (454)	(Rp bn)	1Q24	1Q23	% YoY	4Q23	% QoQ		% IPS		% Cons	5yr avg
Gross profit         625         483         29.4%         751         -16.7%         Coperating cost         (133)         (121)         (245)         Coperating cost         (133)         (121)         (245)         Coperating cost         1         492         362         35.7%         506         -2.9%         1,376         36%         1,309         38%         25%           Others         11         18         (41) </td <td>Net sales</td> <td>1,053</td> <td>907</td> <td>16.1%</td> <td>1,205</td> <td>-12.6%</td> <td>3,871</td> <td>27%</td> <td>3,773</td> <td>28%</td> <td>23%</td>	Net sales	1,053	907	16.1%	1,205	-12.6%	3,871	27%	3,773	28%	23%
Comparising cost   Comparising	COGS	(428)	(424)		(454)						
Cithers	Gross profit	625	483	29.4%	751	-16.7%					
Others         11         18         (41)         PBT         503         380         32.2%         465         8.2%         4.2%         4.7%         8.2%         4.2%         4.7%         8.2%         4.2%         4.7%         8.2%         8.2%         8.2%         8.2%         8.2%         8.2%         8.2%         8.2%	Operating cost	(133)	(121)		(245)						
PBT   503   380   32.2%   465   8.2%	EBIT	492	362	35.7%	506	-2.9%	1,376	36%	1,309	38%	25%
Tax	Others	11	18		(41)						
Net profit         390         300         30.0%         364         7.3%         1,105         35%         1,036         38%         22%           Margin (%)         Gross margin         59.3%         53.3%         6.1%         62.3%         -3.0%         -3.0%         -8.7%         -3.0%         -2.0%         -3.0%         -3.0%         -3.0%         -2.0%         -3.0%         -2.0%	PBT	503	380	32.2%	465	8.2%					
Margin (%)         Gross margin       59.3%       53.3%       6.1%       62.3%       -3.0%         EBIT margin       46.7%       39.9%       6.7%       42.0%       4.7%         Net margin       37.1%       33.1%       4.0%       30.2%       6.8%         Segment information         Revenue         Herbal medicine and supplement       627       553       13.3%       893       -29.8%         Food and beverages       396       331       19.8%       282       40.6%         Pharmacy       30       23       30.6%       30       0.5%         Gross profit         Herbal medicine and supplement       448       374       19.7%       631       -29.0%	Tax	(112)	(80)		(101)						
Gross margin 59.3% 53.3% 6.1% 62.3% -3.0% EBIT margin 46.7% 39.9% 6.7% 42.0% 4.7% Net margin 37.1% 33.1% 4.0% 30.2% 6.8%  Segment information Revenue Herbal medicine and supplement 627 553 13.3% 893 -29.8% Food and beverages 396 331 19.8% 282 40.6% Pharmacy 30 23 30.6% 30 0.5%  Gross profit Herbal medicine and supplement 448 374 19.7% 631 -29.0%	Net profit	390	300	30.0%	364	7.3%	1,105	35%	1,036	38%	22%
Gross margin 59.3% 53.3% 6.1% 62.3% -3.0%  EBIT margin 46.7% 39.9% 6.7% 42.0% 4.7%  Net margin 37.1% 33.1% 4.0% 30.2% 6.8%  Segment information  Revenue  Herbal medicine and supplement 627 553 13.3% 893 -29.8%  Food and beverages 396 331 19.8% 282 40.6%  Pharmacy 30 23 30.6% 30 0.5%  Gross profit  Herbal medicine and supplement 448 374 19.7% 631 -29.0%	Manain (0()										
EBIT margin 46.7% 39.9% 6.7% 42.0% 4.7% Net margin 37.1% 33.1% 4.0% 30.2% 6.8%  Segment information Revenue Herbal medicine and supplement 627 553 13.3% 893 -29.8% Food and beverages 396 331 19.8% 282 40.6% Pharmacy 30 23 30.6% 30 0.5%  Gross profit Herbal medicine and supplement 448 374 19.7% 631 -29.0%		FO 00/	FO 00/	C 10/	CO 00/	0.00/					
Net margin       37.1%       33.1%       4.0%       30.2%       6.8%         Segment information         Revenue       4.0%       4.0%       4.0%       4.0%       4.0%         Herbal medicine and supplement       627       553       13.3%       893       -29.8%         Food and beverages       396       331       19.8%       282       40.6%         Pharmacy       30       23       30.6%       30       0.5%         Gross profit         Herbal medicine and supplement       448       374       19.7%       631       -29.0%	_										
Segment information           Revenue         Herbal medicine and supplement         627         553         13.3%         893         -29.8%           Food and beverages         396         331         19.8%         282         40.6%           Pharmacy         30         23         30.6%         30         0.5%           Gross profit           Herbal medicine and supplement         448         374         19.7%         631         -29.0%											
Revenue         Herbal medicine and supplement       627       553       13.3%       893       -29.8%         Food and beverages       396       331       19.8%       282       40.6%         Pharmacy       30       23       30.6%       30       0.5%         Gross profit         Herbal medicine and supplement       448       374       19.7%       631       -29.0%	Net Hargin	37.1%	33.1%	4.0%	30.2%	0.0%					
Revenue         Herbal medicine and supplement       627       553       13.3%       893       -29.8%         Food and beverages       396       331       19.8%       282       40.6%         Pharmacy       30       23       30.6%       30       0.5%         Gross profit         Herbal medicine and supplement       448       374       19.7%       631       -29.0%	Segment information										
Food and beverages 396 331 19.8% 282 40.6% Pharmacy 30 23 30.6% 30 0.5%  Gross profit Herbal medicine and supplement 448 374 19.7% 631 -29.0%	•										
Pharmacy 30 23 30.6% 30 0.5%  Gross profit  Herbal medicine and supplement 448 374 19.7% 631 -29.0%	Herbal medicine and supplement	627	553	13.3%	893	-29.8%					
Gross profit Herbal medicine and supplement 448 374 19.7% 631 -29.0%	Food and beverages	396	331	19.8%	282	40.6%					
Herbal medicine and supplement 448 374 19.7% 631 -29.0%	Pharmacy	30	23	30.6%	30	0.5%					
Herbal medicine and supplement 448 374 19.7% 631 -29.0%											
	Gross profit										
Food and beverages 166 103 60.5% 110 51.3%	Herbal medicine and supplement	448	374	19.7%	631	-29.0%					
100 100 00.070	Food and beverages	166	103	60.5%	110	51.3%					
Pharmacy 11 6 97.7% 10 14.8%	Pharmacy	11	6	97.7%	10	14.8%					
GPM	CDM										
Herbal medicine and supplement 71.5% 67.6% 3.8% 70.7% 0.7%		71 50/	67 6%	3 80/	70 7%	0.79/					
Food and beverages 41.8% 31.2% 10.6% 38.9% 2.9%	• •										
Pharmacy 37.8% 24.9% 12.8% 33.1% 4.7%											

Source: Company, Indo Premier

## **INDOPREMIER**

Fig. 2: SIDO earnings changes										
	Previous				Current			Changes		
	2024F	2025F	2026F	2024F	2025F	2026F	2024F	2025F	2026F	
Financial Perform. (Rp bn)										
Net sales	3,871	4,181	4,515	3,995	4,376	4,701	3.2%	4.7%	4.1%	
Gross profit	2,202	2,384	2,580	2,366	2,592	2,787	7.4%	8.8%	8.0%	
EBIT	1,376	1,488	1,610	1,513	1,655	1,777	10.0%	11.2%	10.4%	
EBITDA	1,478	1,598	1,728	1,615	1,765	1,896	9.3%	10.5%	9.7%	
Net profit	1,105	1,192	1,286	1,212	1,322	1,416	9.7%	10.9%	10.1%	
EPS (Rp)	37	40	43	40	44	47	9.7%	10.9%	10.1%	
Profitability (%)										
Gross margin	56.9%	57.0%	57.1%	59.2%	59.2%	59.3%	2.3%	2.2%	2.1%	
EBIT margin	35.5%	35.6%	35.7%	37.9%	37.8%	37.8%	2.3%	2.2%	2.1%	
Net profit margin	28.5%	28.5%	28.5%	30.3%	30.2%	30.1%	1.8%	1.7%	1.6%	
Sales breakdown										
Herbal medicine and supplement	2,536	2,739	2,958	2,583	2,815	3,013	1.9%	2.8%	1.8%	
Food and beverages	1,190	1,285	1,388	1,267	1,394	1,506	6.5%	8.5%	8.5%	
Pharmacy	145	156	169	145	166	183	0.0%	6.5%	8.5%	

Source: Company, Indo Premier

Fig. 3: SIDO is currently trading at 17.4x 12M forward P/E, or around 0.7 s.d. below its historical 5-year mean



Source: Bloomberg, Company, Indo Premier

2026F

2025F

# **INDOPREMIER**

moonic otatement (itp bii)	LULLA			LULUI	LULUI
Net revenue	3,866	3,566	3,995	4,376	4,701
Cost of sales	(1,697)	(1,547)	(1,629)	(1,784)	(1,914)
Gross profit	2,169	2,019	2,366	2,592	2,787
SG&A Expenses	(794)	(775)	(853)	(937)	(1,010)
Operating profit	1,375	1,244	1,513	1,655	1,777
Net interest	27	29	42	41	39
Others	18	(53)	0	0	0
Pre-tax income	1,420	1,220	1,555	1,696	1,817
Income tax	(315)	(269)	(343)	(374)	(401)
Net income	1,105	951	1,212	1,322	1,416
Balance Sheet (Rp bn)	2022A	2023A	2024F	2025F	2026F
Cash & equivalent	923	830	906	711	504
Receivable	689	791	828	907	974
Inventory	543	408	362	396	425
Other current assets	40	38	38	38	38
Total current assets	2,194	2,067	2,134	2,052	1,941
Fixed assets	1,611	1,555	1,659	1,748	1,830
Other non-current assets	91	91	91	91	91
Total non-current assets	1,887	1,824	1,928	2,018	2,100
Total assets	4,081	3,891	4,062	4,070	4,041
ST loans	0	0	0	0	0
Payable	209	187	209	229	245
Other payables	176	141	109	119	128
Current portion of LT loans	0	0	0	0	0
Total current liab.	541	462	488	533	572
Long term loans	0	0	0	0	0
Other LT liab.	35	43	44	46	47
Total liabilities	576	505	532	579	620
Equity	2,152	2,152	2,152	2,152	2,152
Retained earnings	1,354	1,234	1,380	1,341	1,272
Minority interest	0	0	0	0	0
Total SHE + minority int.	3,505	3,386	3,532	3,493	3,424
Total liabilities & equity	4,081	3,891	4,064	4,072	4,043
Source: Company Indo Promier	,	,	,	,	

2022A

2023A

2024F

Source: Company, Indo Premier

Income Statement (Rp bn)

2026F

2025F

# **INDOPREMIER**

Net income	1,105	951	1,212	1,322	1,416
Depr. & amortization	185	287	100	110	118
Changes in working capital	(261)	(307)	34	(67)	(57)
Others	5	6	0	0	0
Cash flow from operating	1,033	937	1,346	1,365	1,477
Capital expenditure	(115)	(161)	(204)	(200)	(200)
Others	(60)	(45)	1	2	2
Cash flow from investing	(175)	(206)	(202)	(198)	(198)
Loans	0	0	0	0	0
Equity	3	3	0	0	0
Dividends	(1,086)	(1,068)	(1,068)	(1,361)	(1,485)
Others	13	31	0	0	0
Cash flow from financing	(1,070)	(1,034)	(1,068)	(1,361)	(1,485)
Changes in cash	(212)	(303)	75	(195)	(207)
Key Ratios	2022A	2023A	2024F	2025F	2026F
Gross margin	56.1%	56.6%	59.2%	59.2%	59.3%
Operating margin	35.6%	34.9%	37.9%	37.8%	37.8%
Pre-tax margin	36.7%	34.2%	38.9%	38.8%	38.6%
Net margin	28.6%	26.7%	30.3%	30.2%	30.1%
ROA	27.1%	23.8%	29.8%	32.5%	35.0%
ROE	31.3%	28.8%	35.0%	37.6%	41.0%
Acct. receivables TO (days)	33.6	34.7	34.7	34.7	34.7
Acct. receivables - other TO					
(days)	30.1	40.8	40.8	40.8	40.8
Inventory TO (days)	107.3	112.2	81.1	81.1	81.1
Payable TO (days)	42.8	46.8	46.8	46.8	46.8
Acct. payables - other TO (days)	2.6	2.2	2.2	2.2	2.2
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%
Interest coverage ratio (x)	1762.4	1826.3	NA	NA	NA
Net gearing	-26.3%	-24.5%	-25.6%	-20.4%	-14.7%

2022A

2023A

2024F

Source: Company, Indo Premier

Cash Flow Statement (Rp bn)



#### **INVESTMENT RATINGS**

BUY : Expected total return of 10% or more within a 12-month period

HOLD : Expected total return between -10% and 10% within a 12-month period

SELL : Expected total return of -10% or worse within a 12-month period

#### **ANALYSTS CERTIFICATION**

The views expressed in this research report accurately reflect the analyst's personal views about any and all of the subject securities or issuers; and no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.

#### **DISCLAIMERS**

This research is based on information obtained from sources believed to be reliable, but we do not make any representation or warranty nor accept any responsibility or liability as to its accuracy, completeness or correctness. Opinions expressed are subject to change without notice. This document is prepared for general circulation. Any recommendations contained in this document do not have any regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is not and should not be construed as an offer or a solicitation of an offer to purchase or subscribe or sell any securities. PT Indo Premier Sekuritas or its affiliates may seek or will seek investment banking or other business relationships with the companies in this report.